Slides
Page 1
3Q26 Earnings Presentation October 28, 2026
Page 2
Disclaimer 2 Forward-looking statements are exclusively related to the prospects of the business, its operating and financial results, and pr ospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business a nd its continued access to capital to fund its business plan. These forward-looking statements substantially depend on the market conditions, government re gulations, competitive pressures, the performance of the Brazilian economy and the industry, among other factors, as well as the risks shown in our filed disclosure documents, and are therefore subject to change without prior notice. In addition, unaudited information herein reflects management's interpretation of information taken from its financial statem ents and their respective adjustments, which were prepared in accordance with market practices and for the sole purpose of a more detailed and specific analysis of our results. Therefore, these additional considerations and data must also be analyzed and interpreted independently by shareholders and m arket agents, who should carry out their own analysis and draw their own conclusions from the information reported herein. No data or interpret ative analysis provided by our management should be treated as a guarantee of future performance or results and are merely illustrative of our directors ' vision of our results. The management is not responsible for compliance or accuracy of the data from this report, which must be considered as for in formational purposes only, and should not override the analysis of our audited consolidated financial statements for purposes of a decision to invest in our stock, or for any other purpose.
Page 3
3Q26 Highlights 3 6.6% INCREASE IN PHARMACEUTICAL RETAIL SELL-OUT¹ Note: (1) Sell-out PPP (Pharmacy Purchase Price), according to IQVIA; (2) According to IQVIA, in units +1,2 PERCENTAGE POINTS ABOVE THE MARKET GROWTH IN THE CATEGORIES IN WICH THE COMPANY OPERATES SEMAVY SALES START +93,000 UNITS SOLD IN SEPTEMBER +18,000 POINTS OF SALE SOLD SEMAVY IN THE FIRST MONTH OF SALES +11%² MARKET SHARE IN THE INJECTABLE SEMAGLUTIDE MARKET HYPERA PHARMA'S TOP-SELLING PRODUCT ALREADY IN OCTOBER (2nd MONTH OF SALES)
Page 4
Note: (1) 3Q26 vs. 3Q25; (2) Percentage of net revenue; (3) Change in the percentage of net revenue compared to the previous period4 NET REVENUE GROSS MARGIN MARKETING EXPENSES SELLING EXPENSES GENERAL AND ADMINISTRATIVE EXPENSES NET EARNINGS FROM CONTINUING OPERATIONS EBITDA FROM CONTINUING OPERATIONS 3Q26 Results (R$ million) R$ 2,435.8 +9.4%1 61.3%2 +0.1pp3 R$ 414.7 +0.5pp3 R$ 272.2 +0.6pp3 R$ 93.4 +0.0pp3 R$ 782.3 +3.4%1 R$ 527.0 +16.1%1
Page 5
1,579 2,048 (5,610) 763 (139) (70) 554 (57) (28) (7,658) Gross Cash at the end of 2Q26 Cash Flow From Operations PP&E Intangibles 3Q26 Free Cash Flow Financing Cash Flow IoC Gross Cash at the end of 3Q26 Gross Debt at the end of 3Q26 Net Debt at the end of 3Q26 3Q26 Cash Flow (R$ million) 5 Note: Cash Flow from Financing: Includes receipts from issues and new financing and interest on financial investments; PP&E: includes purchase and sale of fixed assets; EBITDA: Considers the LTM EBITDA from Continuing Operations 2.0x EBITDA